Retail sales of alcohol dependence treatment medicines (group N07E according to the EphMRA classification) exceeded 539.6 million rubles in the first half of 2025 (at retail prices, including VAT). A total of 553,200 packages of such products were sold in the first half of the year.  At the same time, according to information from the database “Audit of retail sales of medicines in Russia (total sell out)” by the analytical company RNC Pharma, the ruble dynamics relative to January-June 2024 amounted to 37.8%, and natural demand indicators also grew significantly (+13.5%). Interestingly, sales stagnated in 2024, with real dynamics relative to 2023 at around zero, although the growth rate in rubles was recorded at 13.6%, reflecting inflation and a shift in demand towards more expensive products.

The regional sales structure of the category varies considerably: while 54.6 thousand and 44.9 thousand packages were sold in Moscow and the Moscow Region in the first half of the year, respectively, only 68 and 59 packages were sold in the Nenets Autonomous Okrug and the Chechen Republic during the same period. Dynamic indicators also vary, with Kamchatka Krai becoming the absolute leader in terms of growth in natural consumption (+41%), followed by St. Petersburg (+34%). A decline in demand for medicines to treat alcohol dependence was observed in 19 regions, with the most pronounced dynamics recorded in the mentioned Nenets Autonomous Okrug and the Chechen Republic, where sales fell by almost the same amount, 33% in packages.

The range of products in this group is very small, consisting of seven INNs represented by 11 trademarks and a small selection of homeopathic remedies (seven brands). It is noteworthy that demand for homeopathic remedies has been steadily declining for several years. The absolute leader in terms of market value is the medicine Midzo from Lasa Laboratorios, which accounts for 37% of sales, but its growth is modest, at 5% in rubles, with natural consumption growing at a comparable rate (+4% in packages). The second place belongs to the medicine Metadoxil from MRA with a share of 34.1%. The medicine is used, among other things, as a hangover remedy, and its popularity is steadily growing. Sales in the first half of 2024 increased 3.2 times in rubles, and the total number of packages sold in the first six months of this year (95,000) is comparable to the sales results for the whole of 2024. Third place, with an 11.1% share in terms of monetary volume, goes to the classic disulfiram preparations under the Teturam brand from three different manufacturers. The ruble dynamics here are relatively modest, at 5%, but this product is the absolute leader in terms of natural consumption volume (177,300 packages).

Naltrexone, the main volume of which is represented on the market by Moscow Endocrine Plant, and Selincro from Lundbeck also showed noticeable growth in the top rankings, both growing at comparable rates of 25% in rubles. Outside the top ten, we note the medicine Ardaleva (R-Pharm), whose sales grew 1.5 times over the year, but whose total retail sales volumes are still very modest at several dozen packages.

Table TOP-10 brands of medicines for the treatment of alcohol dependence (group N07E – according to the EphMRA classifier), by cash sales volume on the Russian retail pharmaceutical market in Q1–Q2 2025